BioCentury
ARTICLE | Clinical News

Talactoferrin: Final Phase I/II data

December 17, 2012 8:00 AM UTC

Final data from a double-blind, U.S. Phase I/II trial in 120 pre-term infants showed that twice-daily 150 mg/kg talactoferrin missed the primary endpoint of reducing the incidence of nosocomial infections vs. placebo (10% vs. 15%, p-value not disclosed). Agennix, which declined to provide additional details, said it does not plan to continue development of talactoferrin in the indication. The trial was funded by a grant from the National Institutes of Health. ...